2. Search Result
Search Result
Results for "

GABA-IN-1

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17599
    Piperazine citrate

    1,4-Diazacyclohexane citrate

    		 GABA Receptor Parasite Infection
    Piperazine (1,4-Diazacyclohexane) citrate is a gamma-aminobutyric acid (GABA) agonist . Piperazine citrate is a vital building block and is an essential core in numerous marketed agents with diverse pharmacological activities .
    Piperazine citrate
  • HY-149399
    GABA-IN-1

    		Others Infection
    GABA-IN-1 (Compound 6) is a GABA inhibitor. GABA-IN-1 has larvicidal activity and insecticidal effect, with mortality rates of 93% at 50 mg/L [1].
    <em>GABA-IN-1</em>
  • HY-106875
    Saripidem

    		GABA Receptor Neurological Disease
    Saripidem is a non-selective ligand for ω modulatory sites of GABA receptor .
    Saripidem
  • HY-N3478
    Isohyenanchin

    HydroxycoriatIN

    		 GABA Receptor Neurological Disease
    Isohyenanchin (Hydroxycoriatin) is an RDLac homo-oligomers antagonist. Isohyenanchin also is a weak antagonist of ionotropic GABA receptors .
    Isohyenanchin
  • HY-124030
    3-Hydroxyphenazepam

    		Drug Metabolite Neurological Disease
    3-Hydroxyphenazepam is an active metabolite of Cinazepam. Cinazepam is a GABAA receptor agonist. 3-Hydroxyphenazepam can inhibit synaptosomal transporter-mediated [ 3H]GABA uptake .
    3-Hydroxyphenazepam
  • HY-103506
    NNC-711 hydrochloride

    NO-711 hydrochloride

    		 GABA Receptor Neurological Disease
    NNC-711 (hydrochloride) is a potent and selective inhibitor of GAT-1 ( GABA transporter 1) with an IC50 of 40 nM for hGAT-1. NNC-711 has anticonvulsant and analgesic effect in vivo and exhibits cognition-enhancing activity [1] .
    NNC-711 hydrochloride
  • HY-15399
    Vigabatrin
    5+ Cited Publications

    γ-VINyl-GABA

    		 GABA Receptor Neurological Disease
    Vigabatrin (γ-Vinyl-GABA), an inhibitory neurotransmitter GABA vinyl-derivative, is an orally active and irreversible GABA transaminase inhibitor. Vigabatrin is an antiepileptic agent, which acts by increasing GABA levels in the brain by inhibiting the catabolism of GABA by GABA transaminase .
    Vigabatrin
  • HY-B0033
    Vigabatrin hydrochloride
    5+ Cited Publications

    γ-VINyl-GABA hydrochloride

    		 GABA Receptor Neurological Disease
    Vigabatrin hydrochloride (γ-Vinyl-GABA hydrochloride), a inhibitory neurotransmitter GABA vinyl-derivative, is an orally active and irreversible GABA transaminase inhibitor. Vigabatrin hydrochloride is an antiepileptic agent, which acts by increasing GABA levels in the brain by inhibiting the catabolism of GABA by GABA transaminase .
    Vigabatrin hydrochloride
  • HY-155305
    BuChE-IN-9

    		Cholinesterase (ChE) Beta-secretase GABA Receptor Neurological Disease
    BuChE-IN-9 (compound 22a) is a potent equine serum-derived BuChE (eqBuChE) inhibitor with an IC50 of 173 nM. BuChE-IN-9 also inhibits human BACE1, Aβ aggregation, mouse GABA transporter 1 (mGAT1) and mGAT4. BuChE-IN-9 has significant antiamnesic properties [1].
    BuChE-IN-9
  • HY-118207
    LU-32-176B

    		GABA Receptor Cancer
    LU-32-176B, a GABA transporter 1(GAT1) selective inhibitor, is found to exert a synergistic anticonvulsant action with GAT2 transport inhibitor EF1502. LU-32-176B inhibits neurons, astrocytes and mGAT1 with the IC50 values of 2μM, 1μM, 4μM, respectively [1] .
    LU-32-176B
  • HY-155238
    E2730

    		GABA Receptor Neurological Disease
    E2730 is a noncompetitive but selective inhibitor of gamma-aminobutyric acid (GABA) transporter 1 (GAT1) with orally available and antiepileptic activity. E2730-mediated GAT1 inhibition is positively correlated with environmental GABA levels and selectively inhibits GAT1-mediated GABA uptake. E2730 (5-50 mg/kg; po) in rat amygdala ignition model, and in mouse cornea ignition (5-50 mg/kg), drug resistance 6Hz-44mA has demonstrated in vivo efficacy in models of psychomotor epilepsy (5-50 mg/kg), fragile X syndrome (2.5-300 mg/kg), and Dravet syndrome (10 mg/kg, 20 mg/kg) [1].
    E2730

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: